The overall goal of this project is to develop an animal model to study the role of tumor suppressor genes in cancer. Utilizing gene targeting protocols, the development of a mouse with a germ line mutation in one or both p53 tumor suppressor alleles has been achieved. The bulk of the current proposal is devoted to the characterization of these mice for their susceptibility to tumors of various types. Our hypothesis is that the p53- deficient mice should be more prone to the development of tumors, as is seen in the equivalent human inherited cancer susceptibility syndrome, Li- Fraumeni syndrome. Li-Fraumeni families contain a mutated p53 germ line alle which apparently contributes to their higher rate of cancer development. We hope that our p53-deficient mice will serve as a potential animal model for this inherited cancer syndrome.
Five specific aims are planned.
Specific Aim 1 will entail characterization of p53 RNA and protein expression in the tissues of p53- deficient germ line heterozygote mice and homozygote mice.
In Specific Aim 2, the in vitro growth rate, susceptibility to immortalization, and susceptibility to transformation of embryo fibroblasts derived from heterozygote and homozygote animals will be examined.
In Specific Aim 3, the incidence of spontaneous tumors in wild type, heterozygote, and homozyogote animals will be compared. Tumors developed by the p53- deficient mice will be examined by molecular techniques to gain insights into the molecular role of p53 in tumorigenesis.
In Specific Aim 4, p53- deficient heterozygotes and homozygotes will be assessed for accelerated development of cancers following treatment with tissue-specific carcinogens. In addition, the heterozygotes and homozygotes will be bred with oncogene-containing transgenic mice to examine the tumorigenic cooperativity of tissue-specific oncogenes and p53 deficiency.
Specific Aim 5 outlines a novel approach to generate a p53 mutation in the germ line of mice identical to that observed in two Li-Fraumeni families. Such Li- Fraumeni mice should serve as a model for this human inherited cancer susceptibility syndrome. We anticipate that the p53-deficient mice will provide powerful models to test the role of tumor suppressor genes in cancer development. The animals may also provide a more sensitive in vivo screening system for potential carcinogenic substances.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA054897-02
Application #
3199392
Study Section
Pathology B Study Section (PTHB)
Project Start
1992-04-15
Project End
1995-03-31
Budget Start
1993-04-01
Budget End
1994-03-31
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Hinkal, George W; Gatza, Catherine E; Parikh, Neha et al. (2009) Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging. Mech Ageing Dev 130:262-71
Ma, Ou; Cai, Wei-Wen; Zender, Lars et al. (2009) MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res 69:2559-67
van Maanen, Marc; Tidwell, Jennie K; Donehower, Lawrence A et al. (2003) Development of an HIV-based cDNA expression cloning system. Mol Ther 8:167-73
Choi, Jene; Nannenga, Bonnie; Demidov, Oleg N et al. (2002) Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol 22:1094-105
Choi, J; Appella, E; Donehower, L A (2000) The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene. Genomics 64:298-306
Jones, J M; Cui, X S; Medina, D et al. (1999) Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ 10:213-22
Tyner, S D; Choi, J; Laucirica, R et al. (1999) Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53. Mol Carcinog 24:197-208
Jones, S N; Hancock, A R; Vogel, H et al. (1998) Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A 95:15608-12
Venkatachalam, S; Shi, Y P; Jones, S N et al. (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17:4657-67
Jones, S N; Ansari-Lari, M A; Hancock, A R et al. (1996) Genomic organization of the mouse double minute 2 gene. Gene 175:209-13

Showing the most recent 10 out of 23 publications